Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist and weak inverse agonist

Potent non-prostanoid inhibitor of platelet aggregation, acting via the prostacyclin receptor

Irreversible and nonselective Monoamine_oxidase_inhibitor>monoamine oxidase inhibitor (MAOI)

Blue fluorescent labeling reagent

Novel potent antileishmanial and antitrypanosomal agent, offering a more optimal balance of increased solubility, suitable metabolic stability, excellent oral bioavailability (100%), and strong in vivo efficacy in a visceral leishmaniasis mouse model (97%

Inhibitor of mitochondrial Lon protease and activator of DNA damage checkpoints

Potent agonist of the human 5-HT2A and 5-HT2C receptors

Novel Selective and Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase (hAMCase)

Poly(ADP-Ribose) Glycohydrolase (PARG) inhibitor

Novel GPR18 antagonist, blocking the effects of Abn-CBD and NAGly.

Novel inhibitor of advanced stages of breast cancer, targeting multiple cannabinoid anti-tumour pathways

Potent CB1 receptor antagonist

Novel water-soluble nystatin derivative, being fully water-soluble (up to 1 g/mL) with the same potency of Nystatin but with 13.5 times lower toxicity

Cancer-testis antigen (CTA) with re-expression in numerous cancer types, eliciting spontaneous humoral and cellular immune responses, restricting expression pattern, being a good candidate target for cancer immunotherapy

Anti-microbial agent against Mycobacterium smegmatis and Mycobacterium bovis BCG, binding to DNA and inducing a unique morphological change to mycobacterial bacilli leading the bacterial cell death

Selective nNOS inhibitor and a5-HT1B/1D receptor agonist

Novel potent Hsp90 inhibitor, inducing tumor regression in a genetically engineered mouse model of glioblastoma multiforme

Highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor

Exceptional oxygen transporter, increasing brain tissue oxygen tension (PbtO2) when administered soon after traumatic brain injury (TBI)

Potent, orally active, small-molecule enhancer of SMN2 splicing, binding to and stabilizing the U1 snRNP:5′ss RNA complex

Negative control for NVS-PAK1-1 (8778)

Novel Potent and Selective inhibitor of YEATS proteins

Novel selective bromodomain and extra-terminal domain (BET) protein family inhibitor (BETi ), inducing an ‘activated’ keratinocyte transcriptional profile with reversal of chronic wound biomarkers in human skin ex vivo

Novel potent PKCθ inhibitor

Specific inhibitor of the 25-hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase)

Novel focal adhesion kinase (FAK) inhibitor, potently blocking kinase activity of FAK along with Aurora A, activated Cdc42-associated kinase 1 (ACK1), Met, insulin receptor (IR), TrkA, and IGF-1R

The first non-peptide somatostatin sst(1) receptor antagonist

Novel nonpeptide bradykinin B1 receptor antagonist

Novel Syk inhibitor

Novel peptide deformylase (PDF) inhibitor; Antibacterial